Skip to main content

Table 6 Statistical comparison of pharmacokinetic parameters at the first cycle (Non-Indian population)

From: Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab

Parameter

Geometric mean

90% CI

BCD-021

Reference bevacizumab

Cmax (μg/ml)

420.93

422.53

89.12% - 111.35%

AUC (μg·h/ml)

54556.29

57999.13

80.67% - 109.69%